<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Non-coronary cardiac manifestations of systemic lupus erythematosus in adults</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Non-coronary cardiac manifestations of systemic lupus erythematosus in adults</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Non-coronary cardiac manifestations of systemic lupus erythematosus in adults</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Karen H Costenbader, MD, MPH</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">David S Pisetsky, MD, PhD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Siobhan M Case, MD, MHS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Nov 04, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Cardiac disease is common among patients with systemic lupus erythematosus (SLE). Cardiac involvement in SLE can be summarized as follows:</p><p class="bulletIndent1"><span class="glyph">●</span>Valvular disease</p><p class="bulletIndent1"><span class="glyph">●</span>Pericardial disease</p><p class="bulletIndent1"><span class="glyph">●</span>Myocardial dysfunction</p><p class="bulletIndent1"><span class="glyph">●</span>Coronary artery disease</p><p></p><p>This topic review will focus on the non-coronary artery disease-related cardiac disorders associated with SLE in adults; coronary heart disease in SLE is presented separately (see  <a class="medical medical_review" href="/d/html/4683.html" rel="external">"Coronary artery disease in systemic lupus erythematosus"</a>). Overviews of the clinical manifestations of SLE in adults and children and a discussion of cardiac disease associated with SLE in children are also discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/6420.html" rel="external">"Childhood-onset systemic lupus erythematosus (SLE): Clinical manifestations and diagnosis", section on 'Cardiac'</a> and  <a class="medical medical_review" href="/d/html/4668.html" rel="external">"Clinical manifestations and diagnosis of systemic lupus erythematosus in adults", section on 'Clinical manifestations'</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">VALVULAR DISEASE</span></p><p class="headingAnchor" id="H3182765422"><span class="h2">Clinical manifestations</span><span class="headingEndMark"> — </span>Valvular involvement in patients with systemic lupus erythematosus (SLE) ranges from mitral valve prolapse to valvular vegetations consistent with nonbacterial thrombotic endocarditis (NBTE, Libman-Sacks endocarditis, verrucous endocarditis) [<a href="#rid1">1</a>]. Vegetations can be associated with valvular dysfunction, most commonly regurgitation. Most patients with vegetations are asymptomatic until embolization occurs (see  <a class="medical medical_review" href="/d/html/91781.html" rel="external">"Nonbacterial thrombotic endocarditis", section on 'Clinical presentation and evaluation'</a>). Unlike many other manifestations of SLE that are more frequent and severe during flares of disease activity, valvular lesions in SLE may occur at any time, and their presence does not correlate with disease activity.</p><p>Mitral valve prolapse appears to occur with increased frequency in patients with SLE, with estimates of it occurring in 21 percent of SLE cases versus 5.5 percent of controls in one study [<a href="#rid2">2</a>]. (See  <a class="medical medical_review" href="/d/html/8172.html" rel="external">"Mitral valve prolapse: Clinical manifestations and diagnosis"</a>.)</p><p>In a report of 342 patients with SLE, 38 (11 percent) had verrucous lesions detected by transthoracic echocardiogram (TTE) [<a href="#rid3">3</a>]. Similar point prevalence rates (6 to 10 percent) have been noted in other studies using TTE [<a href="#rid4">4</a>]. As noted above, however, a higher prevalence (43 percent) has been noted when more sensitive transesophageal echocardiogram (TEE) is performed [<a href="#rid4">4,5</a>]. The clinical presentation, diagnosis, and management of NBTE is discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/91781.html" rel="external">"Nonbacterial thrombotic endocarditis"</a>.)</p><p>Valvular nodules, regurgitation, and NBTE appear to be more prevalent among patients with significantly elevated levels of antiphospholipid antibodies (aPL) [<a href="#rid6">6-10</a>].</p><p>A meta-analysis of 23 primary echocardiographic studies, including 1656 SLE patients (668 with and 988 without aPL) and 508 cases of heart valvular disease, found a greater than 3-fold significantly elevated risk of valvular disease and 3.5-fold elevated risk of NBTE among those with aPL, compared with those without aPL. The risk of valvular disease was highest for lupus anticoagulant (odds ratio [OR] 5.9, 95% CI 2.9-11.8) and immunoglobulin G (IgG) anticardiolipin antibodies (OR 5.6, 95% CI 3.5-9.0) [<a href="#rid6">6</a>]. Another meta-analysis of 21 studies, including 2163 SLE patients, of whom 23.3 percent had valvular lesions, also reported a statistically significant but relatively lower association between anticardiolipin antibodies positivity with valvular lesions (relative risk [RR] 1.6, 95% CI 1.1-2.2) [<a href="#rid11">11</a>]. Mitral valve lesions were the most common, and mitral regurgitation accounted for 19.7 percent of lesions. Other commonly found lesions were mitral valve prolapse (in 9.3 percent of patients) and tricuspid regurgitation (in 10.9 percent of patients). (See  <a class="medical medical_review" href="/d/html/4667.html" rel="external">"Clinical manifestations of antiphospholipid syndrome", section on 'Cardiac involvement'</a>.)</p><p class="headingAnchor" id="H5"><span class="h2">Diagnosis</span><span class="headingEndMark"> — </span>Although serial echocardiographic examination in asymptomatic SLE patients is not warranted to detect the presence of valvular disease, a high index of suspicion should be present in patients with SLE, particularly in those with high titer aPL; an echocardiogram may be useful in those patients, in particular, if a murmur is detected. Cardiac auscultation should be performed at regular visits, followed by echocardiogram in patients with significant or changing murmurs or changing cardiac function. TEE may be necessary for detection of small valvular lesions [<a href="#rid4">4</a>]. (See  <a class="medical medical_review" href="/d/html/91781.html" rel="external">"Nonbacterial thrombotic endocarditis", section on 'Echocardiography'</a>.)</p><p>Blood cultures and echocardiography should be performed when a fever or a new murmur is noted in a patient with SLE. We do not typically perform screening echocardiography in the absence of symptoms or physical findings suggestive of valvular heart disease. Bacterial and other causes of NBTE, including cancer-associated marantic endocarditis and atypical infections such as Q fever, are also on the differential diagnosis [<a href="#rid12">12,13</a>].</p><p class="headingAnchor" id="H6"><span class="h2">Preventing bacterial endocarditis</span><span class="headingEndMark"> — </span>The indications and regimens used for antimicrobial prophylaxis to prevent infective endocarditis after invasive or dental procedures are discussed elsewhere (see  <a class="medical medical_review" href="/d/html/2147.html" rel="external">"Prevention of endocarditis: Antibiotic prophylaxis and other measures"</a>). Patients with SLE and valve lesions who are immunosuppressed may represent a high-risk group for bacterial endocarditis that is not considered in the American College of Cardiology/American Heart Association guidelines (see  <a class="medical medical_review" href="/d/html/2147.html" rel="external">"Prevention of endocarditis: Antibiotic prophylaxis and other measures"</a>). We administer antibiotic prophylaxis before procedures associated with bacteremia for immunosuppressed SLE patients with known valve disease.</p><p class="headingAnchor" id="H7"><span class="h2">Therapy</span><span class="headingEndMark"> — </span>The management of patients with SLE and NBTE usually consists of anticoagulation along with treatment of the underlying disease. A detailed discussion of the management of NBTE can be found elsewhere (see  <a class="medical medical_review" href="/d/html/91781.html" rel="external">"Nonbacterial thrombotic endocarditis", section on 'Treatment'</a>). Glucocorticoid and/or cytotoxic therapy as well as antiplatelet and anticoagulant therapy do not appear to reduce the size of valvular lesions, although there have been no prospective trials. Whether anticoagulation should be recommended for patients with aPL-associated vegetations who have never had any thromboembolic event is less clear and is discussed separately. (See  <a class="medical medical_review" href="/d/html/4682.html" rel="external">"Management of antiphospholipid syndrome", section on 'Cardiac disease'</a>.)</p><p>Valve replacement surgery or valve repair may be necessary for some patients who develop severe mitral or aortic valve regurgitation, or rarely for those with symptomatic stenotic lesions.</p><p class="headingAnchor" id="H8"><span class="h1">PERICARDIAL DISEASE</span><span class="headingEndMark"> — </span>Pericardial involvement is the most common echocardiographic lesion in systemic lupus erythematosus (SLE) and is the most frequent cause of symptomatic cardiac disease [<a href="#rid14">14</a>]. Pericardial effusion occurs at some point in over one-half of patients, and pericarditis may precede the clinical signs of SLE.</p><p class="headingAnchor" id="H9"><span class="h2">Clinical manifestations and diagnosis</span><span class="headingEndMark"> — </span>Pericardial disease may be asymptomatic and often found by echocardiography performed for some other reason [<a href="#rid14">14</a>]. Pericarditis, as with other types of serositis, most often occurs when SLE is active in other organs as well [<a href="#rid15">15</a>]. Large effusions and tamponade, as well as constrictive pericarditis, do occur in SLE [<a href="#rid16">16,17</a>].</p><p>Symptomatic pericarditis typically presents with pleuritic substernal chest pain, often with an audible rub on auscultation. There may also be signs of serositis at other sites (such as pleural effusion and ascites). Some patients may just have chest pain in the absence of the physical findings associated with pericarditis. The workup for pericarditis should include an evaluation for findings suggestive of active disease as well as consideration of other entities commonly seen in SLE, such as pleuritis, pulmonary embolism, and angina. Since progression to tamponade can occur in patients with SLE, patients with pericardial effusion should be closely watched for its development. The evaluation for suspected acute pericarditis and cardiac tamponade is discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/4940.html" rel="external">"Acute pericarditis: Clinical presentation and diagnosis", section on 'Diagnostic evaluation'</a> and  <a class="medical medical_review" href="/d/html/4921.html" rel="external">"Cardiac tamponade"</a>.)</p><p>In clinical practice, measuring antinuclear antibodies (ANA), measuring complement components, or assaying for immune complexes in pericardial fluid is not helpful and just reflects the results of similar tests on peripheral blood samples. The pericardial fluid may contain ANA, phagocytic cells containing nuclei (lupus erythematosus [LE] cells), low complement levels, and immune complexes similar to those seen in SLE-related pleural effusions. The glucose concentration is normal, and the protein concentration is variable, being low with a transudate and elevated with an exudate. The pericardium may reveal foci of inflammatory lesions with immune complexes. There is usually a predominance of mononuclear cells, but scarring may be the primary finding in healed disease. Purulent pericarditis may occur, typically in an immunosuppressed, debilitated patient.</p><p>Pericardiocentesis may be indicated to exclude potentially life-threatening causes of pericarditis (eg, purulent, tuberculous, or neoplastic pericarditis) or to drain the fluid if there are signs of tamponade. (See  <a class="medical medical_review" href="/d/html/4940.html" rel="external">"Acute pericarditis: Clinical presentation and diagnosis", section on 'Pericardiocentesis and pericardial biopsy'</a> and  <a class="medical medical_review" href="/d/html/4921.html" rel="external">"Cardiac tamponade"</a>.)</p><p>In the absence of fever or a documented infection that could predispose to purulent pericarditis or signs of tamponade, we do not routinely perform pericardiocentesis in patients with SLE and pericarditis unless they do not respond to treatment and continue to have symptoms and a persistent pericardial effusion.</p><p class="headingAnchor" id="H10"><span class="h2">Course and treatment</span><span class="headingEndMark"> — </span>Pericarditis resolves in the large majority of SLE patients [<a href="#rid15">15</a>]. It is often a manifestation of an SLE flare and thus <a class="drug drug_general" data-topicid="8541" href="/d/drug information/8541.html" rel="external">hydroxychloroquine</a>, with a short course of a nonsteroidal antiinflammatory drug (NSAID) or a medium- to low-dose glucocorticoid taper are first-line therapies [<a href="#rid18">18</a>]. (See  <a class="medical medical_review" href="/d/html/15800.html" rel="external">"Acute pericarditis: Treatment and prognosis"</a>.)</p><p><a class="drug drug_general" data-topicid="9293" href="/d/drug information/9293.html" rel="external">Colchicine</a> may reduce the risk of recurrence of idiopathic pericarditis [<a href="#rid19">19</a>], but the effectiveness of this agent in patients with SLE is uncertain. Use of colchicine may be tried in patients with SLE whose effusion does not respond to NSAIDs and/or glucocorticoids and, in a past case series, was effective within 1 to 30 days [<a href="#rid20">20</a>]. As colchicine can suppress the bone marrow, the complete blood count should be monitored closely in SLE patients taking colchicine (see  <a class="medical medical_review" href="/d/html/15800.html" rel="external">"Acute pericarditis: Treatment and prognosis", section on 'Colchicine'</a>). Patients with recurrent and severe pericarditis in the setting of active SLE often require immunosuppression with a drug such as <a class="drug drug_general" data-topicid="9026" href="/d/drug information/9026.html" rel="external">azathioprine</a>, <a class="drug drug_general" data-topicid="9670" href="/d/drug information/9670.html" rel="external">mycophenolate</a> mofetil, or <a class="drug drug_general" data-topicid="16479" href="/d/drug information/16479.html" rel="external">belimumab</a> [<a href="#rid18">18</a>]. (See  <a class="medical medical_review" href="/d/html/4944.html" rel="external">"Recurrent pericarditis", section on 'Other immune therapy'</a>.)</p><p>Percutaneous drainage with echocardiographic guidance is effective in treating cardiac tamponade; surgical drainage and pericardiectomy are rarely needed but may be necessary if there is a loculated effusion. (See  <a class="medical medical_review" href="/d/html/4921.html" rel="external">"Cardiac tamponade"</a>.)</p><p class="headingAnchor" id="H11"><span class="h1">MYOCARDITIS</span><span class="headingEndMark"> — </span>Myocarditis is a dangerous but often asymptomatic manifestation of systemic lupus erythematosus (SLE), with a prevalence of 8 to 25 percent [<a href="#rid21">21,22</a>]. Risk for myocarditis may be higher in Black populations compared with White populations or those of Hispanic ethnicity [<a href="#rid21">21,23</a>]. Global or patchy hypokinesis, not in a specific coronary artery distribution, may be an echocardiographic indication of myocarditis and is present in approximately 6 percent of patients with SLE [<a href="#rid1">1</a>].</p><p class="headingAnchor" id="H12"><span class="h2">Clinical manifestations and diagnosis</span><span class="headingEndMark"> — </span>Myocarditis should be suspected with the following findings: tachycardia disproportionate to body temperature, electrocardiographic abnormalities (such as diffuse ST and T wave abnormalities), unexplained cardiomegaly, or symptoms of heart failure. The cardiomegaly may be associated with symptoms and signs of heart failure, conduction abnormalities, and/or arrhythmias [<a href="#rid1">1</a>]. Echocardiography may reveal abnormalities in both systolic and diastolic function of the left ventricle.</p><p>Acute myocarditis may accompany other acute manifestations of active SLE, particularly pericarditis. It can also occur subacutely. Among the many causes of cardiomyopathy, drug-induced (eg, due to high-dose <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a>, long-term antimalarials, phenothiazines) or comorbid disorders (eg, uremia or postpartum cardiomyopathy, viral myocarditis, or infiltrative diseases such as coexistent sarcoidosis or amyloidosis) should be excluded. (See  <a class="medical medical_review" href="/d/html/2812.html" rel="external">"Cardiotoxicity of cancer chemotherapy agents other than anthracyclines, HER2-targeted agents, and fluoropyrimidines", section on 'Cyclophosphamide'</a> and  <a class="medical medical_review" href="/d/html/7964.html" rel="external">"Antimalarial drugs in the treatment of rheumatic disease", section on 'Cardiotoxicity'</a>.)</p><p>Cardiac magnetic resonance imaging (MRI) can help to establish the diagnosis of SLE myocarditis, and right heart catheterization with endomyocardial biopsy should be considered when it is not entirely clear that SLE is active and causing the myocarditis. Cardiac MRI in SLE patients with heart failure can help identify and differentiate acute myocarditis, dilated cardiomyopathy, myocardial infarction, vasculitis, and valvular heart disease. Late gadolinium enhancement is observed in areas of cardiac inflammation [<a href="#rid24">24-28</a>]. Endomyocardial biopsy can distinguish active myocarditis from fibrosis and other causes of cardiomyopathy, and to rule out other causes before proceeding to immunosuppressive therapy [<a href="#rid29">29</a>]. Histologic examination of myocarditis reveals infiltration of the myocardium with mononuclear cells. Inflammation may lead to fibrosis that may be manifested clinically as dilated cardiomyopathy.</p><p>In a study of the diagnostic role of cardiac MRI in detecting myocardial inflammation in SLE and its differentiation from viral myocarditis, 50 patients with suspected infective myocarditis and 25 active SLE patients with cardiac symptoms were assessed by coronary catheterization; endomyocardial biopsy; immunohistologic and polymerase chain reaction (PCR) analysis for viral deoxyribonucleic acid (DNA); and cardiac MRI [<a href="#rid28">28</a>]. When comparing patients with infective myocarditis with patients with active SLE who were found to have myocarditis on MRI, the patients with infective myocarditis were much more likely to be symptomatic than those with active SLE. Over half of all of the patients with myocarditis on MRI had confirmed myocarditis on endomyocardial biopsy. PCR was positive in almost all infective myocarditis patients, but was uncommon in SLE. Thus, due to the subclinical presentation of myocarditis in SLE patients, cardiac MRI may be useful in the diagnosis of SLE myocarditis.</p><p><a class="drug drug_general" data-topicid="8541" href="/d/drug information/8541.html" rel="external">Hydroxychloroquine</a> is also associated with an idiosyncratic cardiotoxicity, and myocardial biopsy may be necessary to rule this out. The characteristic findings of hydroxychloroquine toxicity on light microscopy are diffuse myocyte vacuolization without myocarditis, and transmission electron microscopy demonstrates sarcoplasmic myelinoid and curvilinear inclusion bodies similar to Fabry disease [<a href="#rid30">30,31</a>]. (See  <a class="medical medical_review" href="/d/html/7964.html" rel="external">"Antimalarial drugs in the treatment of rheumatic disease", section on 'Neuromuscular toxicity'</a>.)</p><p class="headingAnchor" id="H13"><span class="h2">Treatment of myocarditis</span><span class="headingEndMark"> — </span>Treatment of lupus myocarditis has not been assessed in controlled trials. As SLE is often active, expert-based treatment guidelines suggest systemic glucocorticoids, intravenous <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a> or <a class="drug drug_general" data-topicid="9670" href="/d/drug information/9670.html" rel="external">mycophenolate</a> mofetil, usually with <a class="drug drug_general" data-topicid="8541" href="/d/drug information/8541.html" rel="external">hydroxychloroquine</a>, as first-line therapy for lupus myocarditis [<a href="#rid18">18</a>]. Improvement in systolic function has been noted in some patients treated with glucocorticoids, other immunosuppressants (eg, cyclophosphamide, <a class="drug drug_general" data-topicid="9026" href="/d/drug information/9026.html" rel="external">azathioprine</a>, or mycophenolate mofetil), or intravenous <a class="drug drug_general" data-topicid="16471" href="/d/drug information/16471.html" rel="external">immune globulin</a> (IVIG) [<a href="#rid1">1,26,32</a>]. Therapy for heart failure is also indicated, if present [<a href="#rid1">1</a>]. (See  <a class="medical medical_review" href="/d/html/121085.html" rel="external">"Overview of the management of heart failure with reduced ejection fraction in adults"</a>.)</p><p>Cardiomyopathy with fibrosis is usually resistant to glucocorticoids and/or immunosuppressive drugs.</p><p class="headingAnchor" id="H14"><span class="h1">CONDUCTION ABNORMALITIES</span></p><p class="headingAnchor" id="H2595967087"><span class="h2">Cardiac arrhythmias</span><span class="headingEndMark"> — </span>Cardiac arrhythmias, which may represent sequelae of active or past myocarditis, have been reported to be highly prevalent among systemic lupus erythematosus (SLE) patients. The most common arrhythmias and electrocardiographic abnormalities observed in SLE populations are sinus tachycardia (18 percent), atrial fibrillation (9 percent), and QT prolongation (17 percent) [<a href="#rid33">33</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>Past observations had suggested a relationship between the presence of anti-Ro/SSA antibodies and QT prolongation in adults. However, large studies have not confirmed this association [<a href="#rid34">34,35</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a cross-sectional study of the large SLE International Collaborating Clinics (SLICC) cohort of 779 SLE patients, the prevalence of electrocardiogram (ECG) abnormalities was nonspecific ST-T changes (30.9 percent), possible left ventricular hypertrophy (5.4 percent), and supraventricular arrhythmias (1.3 percent) [<a href="#rid34">34</a>]. A QT interval (QTc) ≥440 msec was found in 15.3 percent, while a QTc ≥460 msec was found in 5.3 percent. Neither the specificity nor the level of anti-Ro/SSA was associated with QTc duration.</p><p></p><p>As <a class="drug drug_general" data-topicid="8541" href="/d/drug information/8541.html" rel="external">hydroxychloroquine</a> is a QTc-prolonging medication, guidelines for medications associated with potential for QTc prolongation should be followed (see  <a class="medical medical_review" href="/d/html/116011.html" rel="external">"Acquired long QT syndrome: Clinical manifestations, diagnosis, and management"</a>). Baseline 12-lead ECG with QTc measurement prior to initiation of treatment, and repeated ECGs at intervals or when other QTc-prolonging medications are added are advisable in particular for patients at increased risk of torsades de pointes (female, advanced age, taking other QTc-prolonging drugs, underlying coronary artery disease, hypothyroidism, hypokalemia). It is not yet known what proportion of observed ECG abnormalities in past SLE cohort studies were attributable to hydroxychloroquine and, as patients with SLE do have increased risks of coronary and non-coronary heart disease, referral to a cardiologist for evaluation of ECG abnormalities is often indicated and helpful. (See  <a class="medical medical_review" href="/d/html/7964.html" rel="external">"Antimalarial drugs in the treatment of rheumatic disease", section on 'Cardiotoxicity'</a>.)</p><p>First-degree heart block may be seen in patients with SLE, and they are at increased risk of higher degrees of heart block and arrhythmias (such as atrial fibrillation) [<a href="#rid36">36</a>]. Autopsy studies have revealed focal inflammatory cell infiltrates or, more often, fibrous scarring of the conduction system.</p><p>It should be noted that chronic resting tachycardia in SLE patients has been associated with increased disease activity, poor physical function, and possible subclinical serositis or pancarditis [<a href="#rid37">37</a>].</p><p class="headingAnchor" id="H17"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>Non-coronary cardiac manifestations are common in systemic lupus erythematosus (SLE) and should be high on the differential of presentation with tachycardia, electrocardiographic abnormalities, a cardiac murmur, chest pain or tightness, shortness of breath, palpitations, or pedal edema. Valvular disease, pericardial and myocardial inflammation, arrhythmias, and coronary heart disease occur at high rates in patients with SLE. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Valvular involvement in patients with SLE ranges from mitral valve prolapse to valvular vegetations consistent with nonbacterial thrombotic endocarditis (NBTE). Although serial echocardiographic examination in asymptomatic SLE patients is not warranted to detect the presence of valvular disease, a high index of suspicion should be present in patients with SLE, particularly in those with high titer antiphospholipid antibodies (aPL), and an echocardiogram may be useful in those patients, in particular, if a murmur is detected (see <a class="local">'Valvular disease'</a> above). The management of NBTE is discussed in detail in a separate topic. (See  <a class="medical medical_review" href="/d/html/91781.html" rel="external">"Nonbacterial thrombotic endocarditis", section on 'Treatment'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Antibiotic prophylaxis is not recommended for most patients with SLE and valvular heart disease. However, patients with SLE and valve lesions who are immunosuppressed may represent a high-risk group not considered in the American College of Cardiology/American Heart Association guidelines. We administer antibiotic prophylaxis before procedures associated with bacteremia for immunosuppressed SLE patients with known valve disease. (See <a class="local">'Preventing bacterial endocarditis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Pericardial disease is a common manifestation of SLE and associated with SLE flares. Pericarditis, as with other types of serositis, most often occurs when SLE is active in other organs as well. Large effusions and tamponade can occur. Pericardiocentesis may be indicated to exclude potentially life-threatening causes of pericarditis (eg, purulent, tuberculous, or neoplastic pericarditis) or to drain the fluid if there are signs of tamponade. (See <a class="local">'Pericardial disease'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Symptomatic acute pericarditis often responds to a nonsteroidal antiinflammatory drug (NSAID) or low-dose glucocorticoid (0.5 mg/kg/day tapered over two to three weeks). <a class="drug drug_general" data-topicid="9293" href="/d/drug information/9293.html" rel="external">Colchicine</a> may reduce the risk of recurrent pericarditis, and we suggest using colchicine (initial dose 1 to 2 mg orally for one day, then 0.5 mg twice daily, orally, for six months) (<a class="grade" href="https://medilib.ir/uptodate/show/grade_5" rel="external">Grade 2B</a>) (see <a class="local">'Course and treatment'</a> above). A reduction in the dose of colchicine is necessary if there is significant impairment in renal function. (See  <a class="medical medical_review" href="/d/html/15800.html" rel="external">"Acute pericarditis: Treatment and prognosis", section on 'Colchicine'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Myocarditis in SLE can be silent or cause resting tachycardia, cardiomegaly, heart failure, conduction abnormalities, and/or arrhythmias. Cardiac MRI is emerging as a useful technique for identifying SLE-related myocardial inflammation, but ultimately, many patients may need endomyocardial biopsy to establish the diagnosis and rule out other causes of myocarditis. <a class="drug drug_general" data-topicid="8541" href="/d/drug information/8541.html" rel="external">Hydroxychloroquine</a> is also associated with an idiosyncratic cardiotoxicity, usually after long-term use, and myocardial biopsy may be necessary to rule this out. (See <a class="local">'Myocarditis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with lupus myocarditis, we suggest initial treatment with high-dose glucocorticoids (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). A typical regimen is <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> 1 mg/kg (or equivalent) intravenously or orally daily for three days tapered to oral prednisone. A glucocorticoid sparing agent such as <a class="drug drug_general" data-topicid="9670" href="/d/drug information/9670.html" rel="external">mycophenolate</a> mofetil, <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a>, or <a class="drug drug_general" data-topicid="9026" href="/d/drug information/9026.html" rel="external">azathioprine</a> is also typically initiated. For those with heart failure, this is accompanied by treatment for ventricular dysfunction. (See <a class="local">'Treatment of myocarditis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Cardiac arrhythmias have been reported to be highly prevalent among SLE patients. The most common arrhythmias and electrocardiographic abnormalities observed in SLE populations are sinus tachycardia, atrial fibrillation, and QT prolongation. (See <a class="local">'Cardiac arrhythmias'</a> above.)</p><p></p><p class="headingAnchor" id="H359551088"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Peter Schur, MD, who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Miner JJ, Kim AH. Cardiac manifestations of systemic lupus erythematosus. Rheum Dis Clin North Am 2014; 40:51.</a></li><li><a class="nounderline abstract_t">Evangelopoulos ME, Alevizaki M, Toumanidis S, et al. Mitral valve prolapse in systemic lupus erythematosus patients: clinical and immunological aspects. Lupus 2003; 12:308.</a></li><li><a class="nounderline abstract_t">Moyssakis I, Tektonidou MG, Vasilliou VA, et al. Libman-Sacks endocarditis in systemic lupus erythematosus: prevalence, associations, and evolution. Am J Med 2007; 120:636.</a></li><li><a class="nounderline abstract_t">Roldan CA, Qualls CR, Sopko KS, Sibbitt WL Jr. Transthoracic versus transesophageal echocardiography for detection of Libman-Sacks endocarditis: a randomized controlled study. J Rheumatol 2008; 35:224.</a></li><li><a class="nounderline abstract_t">Roldan CA, Tolstrup K, Macias L, et al. Libman-Sacks Endocarditis: Detection, Characterization, and Clinical Correlates by Three-Dimensional Transesophageal Echocardiography. J Am Soc Echocardiogr 2015; 28:770.</a></li><li><a class="nounderline abstract_t">Zuily S, Regnault V, Selton-Suty C, et al. Increased risk for heart valve disease associated with antiphospholipid antibodies in patients with systemic lupus erythematosus: meta-analysis of echocardiographic studies. Circulation 2011; 124:215.</a></li><li><a class="nounderline abstract_t">Perez-Villa F, Font J, Azqueta M, et al. Severe valvular regurgitation and antiphospholipid antibodies in systemic lupus erythematosus: a prospective, long-term, followup study. Arthritis Rheum 2005; 53:460.</a></li><li><a class="nounderline abstract_t">Turiel M, Sarzi-Puttini P, Peretti R, et al. Five-year follow-up by transesophageal echocardiographic studies in primary antiphospholipid syndrome. Am J Cardiol 2005; 96:574.</a></li><li><a class="nounderline abstract_t">Ruiz D, Oates JC, Kamen DL. Antiphospholipid Antibodies and Heart Valve Disease in Systemic Lupus Erythematosus. Am J Med Sci 2018; 355:293.</a></li><li><a class="nounderline abstract_t">Farzaneh-Far A, Roman MJ, Lockshin MD, et al. Relationship of antiphospholipid antibodies to cardiovascular manifestations of systemic lupus erythematosus. Arthritis Rheum 2006; 54:3918.</a></li><li><a class="nounderline abstract_t">Hussain K, Gauto-Mariotti E, Cattoni HM, et al. A Meta-analysis and Systematic Review of Valvular Heart Disease in Systemic Lupus Erythematosus and Its Association With Antiphospholipid Antibodies. J Clin Rheumatol 2021; 27:e525.</a></li><li><a class="nounderline abstract_t">Costenbader KH, Fidias P, Gilman MD, et al. Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 29-2006. A 43-year-old woman with painful nodules on the fingertips, shortness of breath, and fatigue. N Engl J Med 2006; 355:1263.</a></li><li><a class="nounderline abstract_t">Million M, Walter G, Bardin N, et al. Immunoglobulin G anticardiolipin antibodies and progression to Q fever endocarditis. Clin Infect Dis 2013; 57:57.</a></li><li><a class="nounderline abstract_t">Doria A, Iaccarino L, Sarzi-Puttini P, et al. Cardiac involvement in systemic lupus erythematosus. Lupus 2005; 14:683.</a></li><li><a class="nounderline abstract_t">Man BL, Mok CC. Serositis related to systemic lupus erythematosus: prevalence and outcome. Lupus 2005; 14:822.</a></li><li><a class="nounderline abstract_t">Rosenbaum E, Krebs E, Cohen M, et al. The spectrum of clinical manifestations, outcome and treatment of pericardial tamponade in patients with systemic lupus erythematosus: A retrospective study and literature review. Lupus 2009; 18:608.</a></li><li><a class="nounderline abstract_t">Goswami RP, Sircar G, Ghosh A, Ghosh P. Cardiac tamponade in systemic lupus erythematosus. QJM 2018; 111:83.</a></li><li><a class="nounderline abstract_t">Muangchan C, van Vollenhoven RF, Bernatsky SR, et al. Treatment Algorithms in Systemic Lupus Erythematosus. Arthritis Care Res (Hoboken) 2015; 67:1237.</a></li><li><a class="nounderline abstract_t">Guindo J, Rodriguez de la Serna A, Ramió J, et al. Recurrent pericarditis. Relief with colchicine. Circulation 1990; 82:1117.</a></li><li><a class="nounderline abstract_t">Morel N, Bonjour M, Le Guern V, et al. Colchicine: a simple and effective treatment for pericarditis in systemic lupus erythematosus? A report of 10 cases. Lupus 2015; 24:1479.</a></li><li><a class="nounderline abstract_t">Apte M, McGwin G Jr, Vilá LM, et al. Associated factors and impact of myocarditis in patients with SLE from LUMINA, a multiethnic US cohort (LV). [corrected]. Rheumatology (Oxford) 2008; 47:362.</a></li><li><a class="nounderline abstract_t">du Toit R, Karamchand S, Doubell AF, et al. Lupus myocarditis: review of current diagnostic modalities and their application in clinical practice. Rheumatology (Oxford) 2023; 62:523.</a></li><li><a class="nounderline abstract_t">García MA, Alarcón GS, Boggio G, et al. Primary cardiac disease in systemic lupus erythematosus patients: protective and risk factors--data from a multi-ethnic Latin American cohort. Rheumatology (Oxford) 2014; 53:1431.</a></li><li><a class="nounderline abstract_t">Mavrogeni S, Smerla R, Grigoriadou G, et al. Cardiovascular magnetic resonance evaluation of paediatric patients with systemic lupus erythematosus and cardiac symptoms. Lupus 2016; 25:289.</a></li><li><a class="nounderline abstract_t">Mavrogeni S, Koutsogeorgopoulou L, Markousis-Mavrogenis G, et al. Cardiovascular magnetic resonance detects silent heart disease missed by echocardiography in systemic lupus erythematosus. Lupus 2018; 27:564.</a></li><li><a class="nounderline abstract_t">Thomas G, Cohen Aubart F, Chiche L, et al. Lupus Myocarditis: Initial Presentation and Longterm Outcomes in a Multicentric Series of 29 Patients. J Rheumatol 2017; 44:24.</a></li><li><a class="nounderline abstract_t">Gerster M, Peker E, Nagel E, Puntmann VO. Deciphering cardiac involvement in systemic inflammatory diseases: noninvasive tissue characterisation using cardiac magnetic resonance is key to improved patients' care. Expert Rev Cardiovasc Ther 2016; 14:1283.</a></li><li><a class="nounderline abstract_t">Mavrogeni S, Bratis K, Markussis V, et al. The diagnostic role of cardiac magnetic resonance imaging in detecting myocardial inflammation in systemic lupus erythematosus. Differentiation from viral myocarditis. Lupus 2013; 22:34.</a></li><li><a class="nounderline abstract_t">Schattner A, Liang MH. The cardiovascular burden of lupus: a complex challenge. Arch Intern Med 2003; 163:1507.</a></li><li><a class="nounderline abstract_t">Keating RJ, Bhatia S, Amin S, et al. Hydroxychloroquine-induced cardiotoxicity in a 39-year-old woman with systemic lupus erythematosus and systolic dysfunction. J Am Soc Echocardiogr 2005; 18:981.</a></li><li><a class="nounderline abstract_t">Nord JE, Shah PK, Rinaldi RZ, Weisman MH. Hydroxychloroquine cardiotoxicity in systemic lupus erythematosus: a report of 2 cases and review of the literature. Semin Arthritis Rheum 2004; 33:336.</a></li><li><a class="nounderline abstract_t">Petri M, Spence D, Bone LR, Hochberg MC. Coronary artery disease risk factors in the Johns Hopkins Lupus Cohort: prevalence, recognition by patients, and preventive practices. Medicine (Baltimore) 1992; 71:291.</a></li><li><a class="nounderline abstract_t">Myung G, Forbess LJ, Ishimori ML, et al. Prevalence of resting-ECG abnormalities in systemic lupus erythematosus: a single-center experience. Clin Rheumatol 2017; 36:1311.</a></li><li><a class="nounderline abstract_t">Bourré-Tessier J, Urowitz MB, Clarke AE, et al. Electrocardiographic findings in systemic lupus erythematosus: data from an international inception cohort. Arthritis Care Res (Hoboken) 2015; 67:128.</a></li><li><a class="nounderline abstract_t">Massie C, Hudson M, Tatibouet S, et al. Absence of an association between anti-Ro antibodies and prolonged QTc interval in systemic sclerosis: a multicenter study of 689 patients. Semin Arthritis Rheum 2014; 44:338.</a></li><li><a class="nounderline abstract_t">Chen SK, Barbhaiya M, Fischer MA, et al. Heart failure risk in systemic lupus erythematosus compared to diabetes mellitus and general medicaid patients. Semin Arthritis Rheum 2019; 49:389.</a></li><li><a class="nounderline abstract_t">Utset TO, Ward AB, Thompson TL, Green SL. Significance of chronic tachycardia in systemic lupus erythematosus. Arthritis Care Res (Hoboken) 2013; 65:827.</a></li></ol></div><div id="topicVersionRevision">Topic 4680 Version 26.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24268009" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Cardiac manifestations of systemic lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12729055" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Mitral valve prolapse in systemic lupus erythematosus patients: clinical and immunological aspects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17602939" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Libman-Sacks endocarditis in systemic lupus erythematosus: prevalence, associations, and evolution.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18085739" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Transthoracic versus transesophageal echocardiography for detection of Libman-Sacks endocarditis: a randomized controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25807885" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Libman-Sacks Endocarditis: Detection, Characterization, and Clinical Correlates by Three-Dimensional Transesophageal Echocardiography.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21690492" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Increased risk for heart valve disease associated with antiphospholipid antibodies in patients with systemic lupus erythematosus: meta-analysis of echocardiographic studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15934103" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Severe valvular regurgitation and antiphospholipid antibodies in systemic lupus erythematosus: a prospective, long-term, followup study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16098314" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Five-year follow-up by transesophageal echocardiographic studies in primary antiphospholipid syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29549933" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Antiphospholipid Antibodies and Heart Valve Disease in Systemic Lupus Erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17133599" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Relationship of antiphospholipid antibodies to cardiovascular manifestations of systemic lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32558678" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : A Meta-analysis and Systematic Review of Valvular Heart Disease in Systemic Lupus Erythematosus and Its Association With Antiphospholipid Antibodies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16990390" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 29-2006. A 43-year-old woman with painful nodules on the fingertips, shortness of breath, and fatigue.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23532474" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Immunoglobulin G anticardiolipin antibodies and progression to Q fever endocarditis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16218467" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Cardiac involvement in systemic lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16302677" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Serositis related to systemic lupus erythematosus: prevalence and outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19433460" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : The spectrum of clinical manifestations, outcome and treatment of pericardial tamponade in patients with systemic lupus erythematosus: A retrospective study and literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29048543" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Cardiac tamponade in systemic lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25777803" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Treatment Algorithms in Systemic Lupus Erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2205414" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Recurrent pericarditis. Relief with colchicine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26163661" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Colchicine: a simple and effective treatment for pericarditis in systemic lupus erythematosus? A report of 10 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18250089" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Associated factors and impact of myocarditis in patients with SLE from LUMINA, a multiethnic US cohort (LV). [corrected].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35861382" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Lupus myocarditis: review of current diagnostic modalities and their application in clinical practice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24633413" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Primary cardiac disease in systemic lupus erythematosus patients: protective and risk factors--data from a multi-ethnic Latin American cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26453663" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Cardiovascular magnetic resonance evaluation of paediatric patients with systemic lupus erythematosus and cardiac symptoms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28927316" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Cardiovascular magnetic resonance detects silent heart disease missed by echocardiography in systemic lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28042125" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Lupus Myocarditis: Initial Presentation and Longterm Outcomes in a Multicentric Series of 29 Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27538753" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Deciphering cardiac involvement in systemic inflammatory diseases: noninvasive tissue characterisation using cardiac magnetic resonance is key to improved patients' care.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23035042" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : The diagnostic role of cardiac magnetic resonance imaging in detecting myocardial inflammation in systemic lupus erythematosus. Differentiation from viral myocarditis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12860571" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : The cardiovascular burden of lupus: a complex challenge.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16153529" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Hydroxychloroquine-induced cardiotoxicity in a 39-year-old woman with systemic lupus erythematosus and systolic dysfunction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15079764" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Hydroxychloroquine cardiotoxicity in systemic lupus erythematosus: a report of 2 cases and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1522805" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Coronary artery disease risk factors in the Johns Hopkins Lupus Cohort: prevalence, recognition by patients, and preventive practices.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28238088" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Prevalence of resting-ECG abnormalities in systemic lupus erythematosus: a single-center experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24838943" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Electrocardiographic findings in systemic lupus erythematosus: data from an international inception cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25128430" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Absence of an association between anti-Ro antibodies and prolonged QTc interval in systemic sclerosis: a multicenter study of 689 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31280938" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Heart failure risk in systemic lupus erythematosus compared to diabetes mellitus and general medicaid patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23281192" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Significance of chronic tachycardia in systemic lupus erythematosus.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
